此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

OPTImaL:具有高间质肿瘤浸润淋巴细胞的低期三阴性乳腺癌患者的优化治疗 (OPTImaL)

2026年11月10日 更新者:The Netherlands Cancer Institute

The aim of this study is to investigate whether subjects with breast cancer that have certain favorable features, after performing the surgery and radiation, the chemotherapy can be safely omitted in the treatment. In addition, the investigation looks at whether the omission of chemotherapy ensures a better quality of life. Participants decide, in consultation with their treating physician, whether they choose to be treated with adjuvant chemotherapy or not.

研究概览

研究类型

观察性的

注册 (估计的)

490

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Marleen Kok, MD
  • 电话号码:+31205129111
  • 邮箱:m.kok@nki.nl

研究联系人备份

  • 姓名:Rianne Rolfes, MD
  • 电话号码:+31205129111
  • 邮箱:r.rolfes@nki.nl

学习地点

      • Alkmaar、荷兰
        • 尚未招聘
        • Noordwest Ziekenhuisgroep
        • 接触:
          • S Vrijaldenhoven, MD
        • 首席研究员:
          • S Vrijaldenhoven, MD
      • Almere Stad、荷兰
        • 尚未招聘
        • Flevoziekenhuis
        • 接触:
          • S.A.L. Bartels, MD
        • 首席研究员:
          • S.A.L. Bartels, MD
      • Amersfoort、荷兰
        • 招聘中
        • Meander Medisch Centrum
        • 接触:
          • J M Baas, MD
        • 首席研究员:
          • J M Baas, MD
      • Amsterdam、荷兰、1066 CX
        • 招聘中
        • Antoni van Leeuwenhoek
        • 接触:
          • Marleen Kok, MD
          • 电话号码:9111 +3120512
          • 邮箱:m.kok@nki.nl
        • 接触:
        • 首席研究员:
          • Marleen Kok, MD
      • Amsterdam、荷兰
        • 招聘中
        • Onze Lieve Vrouwe Gasthuis (OLVG)
        • 接触:
          • B Flameling, MD
        • 首席研究员:
          • B Flameling, MD
      • Arnhem、荷兰
        • 招聘中
        • Rijnstate
        • 接触:
          • K Beelen, MD
        • 首席研究员:
          • K Beelen, MD
      • Breda、荷兰
        • 招聘中
        • Amphia ziekenhuis
        • 接触:
          • J Heijns, MD
        • 首席研究员:
          • J Heijns, MD
      • Deventer、荷兰
        • 招聘中
        • Deventer Ziekenhuis
        • 接触:
          • L. Kessels, MD, PhD
        • 首席研究员:
          • L. Kessels, MD, PhD
      • Ede、荷兰
        • 招聘中
        • Ziekenhuis Gelderse Vallei
        • 接触:
          • M Verstappen, MD
        • 首席研究员:
          • M Verstappen, MD
      • Eindhoven、荷兰
        • 招聘中
        • Catharina Ziekenhuis
        • 接触:
          • R-J Schipper, MD
        • 首席研究员:
          • R-J Schipper, MD
      • Eindhoven、荷兰
        • 招聘中
        • Jeroen Bosch ziekenhuis
        • 接触:
          • J Tol, MD
        • 首席研究员:
          • J Tol, MD
      • Harderwijk、荷兰
        • 招聘中
        • St. Jansdal
        • 接触:
          • J A Ropela, MD
        • 首席研究员:
          • J A Ropela, MD
      • Hengelo、荷兰
        • 招聘中
        • Ziekenhuisgroep Twente
        • 接触:
          • E Siemerink, MD
        • 首席研究员:
          • E Siemerink, MD
      • Hilversum、荷兰
        • 招聘中
        • Tergooi ziekenhuizen
        • 接触:
          • A Willemsen, MD
        • 首席研究员:
          • A Willemsen, MD
      • Hoofddorp、荷兰
        • 招聘中
        • Spaarne Gasthuis
        • 首席研究员:
          • B de Valk, MD
        • 接触:
          • B de Valk, MD
      • Hoorn、荷兰
        • 尚未招聘
        • Dijklander ziekenhuis
        • 接触:
          • M M Vleugel, MD
        • 首席研究员:
          • M M Vleugel, MD
      • Leeuwarden、荷兰、8934 AD
        • 尚未招聘
        • MCL
        • 接触:
          • L Hamming, MD
        • 首席研究员:
          • L Hamming, MD
      • Leiden、荷兰
        • 尚未招聘
        • LUMC
        • 接触:
          • J Kroep, MD
        • 首席研究员:
          • J Kroep, MD
      • Maastricht、荷兰
        • 尚未招聘
        • MUMC
        • 接触:
          • M de Boer, MD
        • 首席研究员:
          • M de Boer, MD
      • Nieuwegein、荷兰
        • 招聘中
        • St. Antonius ziekenhuis
        • 接触:
          • M J Agterof, MD
        • 首席研究员:
          • M J Agterof, MD
      • Nijmegen、荷兰、6225GA
        • 尚未招聘
        • Radboud UMC
        • 接触:
          • E Kuip, MD
        • 首席研究员:
          • E Kuip, MD
      • Rotterdam、荷兰、3015CE
        • 尚未招聘
        • Erasmus Medical Center Cancer Institute
        • 接触:
          • A Jager, MD
        • 首席研究员:
          • A Jager, MD
      • Schiedam、荷兰
        • 招聘中
        • Franciscus Gasthuis & Vlietland
        • 接触:
          • J.M. Zuetenhorst, dr.
      • Sittard-Geleen、荷兰、6162 BG
        • 尚未招聘
        • Zuyderland Medisch Centrum
        • 接触:
          • F van den Berkmortel, MD
        • 首席研究员:
          • F van den Berkmortel, MD
      • The Hague、荷兰
        • 招聘中
        • Haaglanden Medisch Centrum
        • 接触:
          • R. Oosterkamp, MD, PhD
        • 首席研究员:
          • R. Oosterkamp, MD, PhD
      • Venlo、荷兰
        • 尚未招聘
        • VieCuri Medisch Centrum voor Noord-Limburg
        • 接触:
          • E Boon, MD
        • 首席研究员:
          • E Boon, MD
      • Zwolle、荷兰
        • 招聘中
        • Isala
        • 接触:
          • A Honkoop, MD
        • 首席研究员:
          • A Honkoop, MD
    • Overijssel
      • Enschede、Overijssel、荷兰、7500 KA
        • 招聘中
        • Medical spectrum Twente
        • 接触:
          • M Wymenga, MD
        • 首席研究员:
          • M Wymenga, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

patients with pathological stage I TNBC (pT1a/b/cN0) and a high sTIL score (defined as ≥50% for patients ≥40 years; ≥75% for patients <40 years)

描述

Inclusion Criteria:

  • Female or male patients;

  • >=18 years;

  • Written informed consent;

  • TNBC (defined as: invasive carcinoma; ER/PR expression 0-9%; Human Epidermal Growth Factor Receptor 2 [HER2] negative [0, 1+ or 2+ on immunohistochemistry, without HER2 amplification on in-situ hybridization]) on the diagnostic biopsy and the surgical specimen;

  • Pathological stage I TNBC (according to the TNM staging 8th edition):

    • pT1a/b/c (≤2 cm), confirmed by an invasive component of ≤2 cm on the surgical specimen (microinvasive disease [pT1mi, ≤1 mm) is not allowed);
    • pN0, confirmed by absence of malignant cells in the sentinel lymph node or any other lymph node after surgery (isolated tumor cells [N0(i+)] are not allowed);
  • No evidence of nodal or distant metastases (cN0M0) on pre and/or postoperative imaging examinations (performed following local/national guidelines, but must include an 18F-fluorodeoxyglucose positron emission tomography/computed tomography [18F-FDG-PET/CT, at least from skull base to upper legs] or computed tomography [CT] of neck/chest/abdomen/pelvis [CT only if 18F-FDG-PET/CT would not be available; 18F-FDG-PET/CT mandatory in the Netherlands]);

  • sTIL score of ≥50% for patients ≥40 years at the time of TNBC diagnosis and ≥75% for patients <40 years at the time of TNBC diagnosis on an H&E FFPE tissue slide on the surgical specimen, according to International Immuno-Oncology Biomarker Working Group on Breast Cancer (formerly International TILs Working Group) guidelines, by local and central review

  • Has undergone curative breast surgery (breast-conserving surgery or mastectomy and surgical axillary staging [including at least sentinel lymph node procedure]);

  • Absence of recurrence between curative breast surgery and expression of patient preference;

  • Eligible for radiotherapy (if indicated).

Exclusion Criteria:

  • Prior disease history of invasive and/or non-invasive breast cancer, or ongoing treatment for invasive and/or non-invasive breast cancer;
  • Multifocal, multicentric or bilateral breast cancer at the time of screening;
  • Administration of neoadjuvant systemic therapy;
  • Presence of lymphovascular invasion on the diagnostic biopsy and/or the surgical specimen;
  • Other invasive malignancy within 5 years prior to inclusion, with the exception of ade-quately treated non-melanoma skin cancer, localized cervical cancer, localized and Gleason ≤6 prostate cancer;
  • Uncontrolled severe illness or medical condition;
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before the enrolment in the in the trial.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Optimisation cohort

patients will be treated with surgery and adjuvant radiotherapy following local/national guidelines, while chemotherapy will be omitted

no adjuvant chemotherapy

Control cohort

patients will be treated with surgery, adjuvant radiotherapy and adjuvant chemotherapy following local/national guidelines

adjuvant chemotherapy according to local/ national guidelines

其他名称:
  • 根据当地/国家指南

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Disease recurrence Free Interval (DRFI) - optimalisation cohort per-protocol population
大体时间:up to 96 months after inclusion of the last patient

Number of patients with distant recurrence or death in per-protocol population of the optimisation cohort

up to 96 months after inclusion of the last patient

次要结果测量

结果测量
措施说明
大体时间
Disease recurrence Free Interval (DRFI) - optimalisation cohort intention to treat population
大体时间:up to 96 months after inclusion of the last patient

Number of patients with distant recurrence or death in intention to treat population of the optimisation cohort

up to 96 months after inclusion of the last patient
Disease recurrence Free Interval (DRFI) - control cohort
大体时间:up to 96 months after inclusion of the last patient

Number of patients with distant recurrence or death in control cohort

up to 96 months after inclusion of the last patient
Invasive disease-free survival (IDFS) - optimalisation cohort per-protocol population
大体时间:up to 96 months after inclusion of the last patient

Number of patients with breast tumor recurrence or death in the per-protocol population of the optimisation cohort

up to 96 months after inclusion of the last patient
Invasive disease-free survival (IDFS) - optimalisation cohort intention-to-treat population
大体时间:up to 96 months after inclusion of the last patient

Number of patients with breast tumor recurrence or death in the the intention-to-treat population of the optimisation cohort

up to 96 months after inclusion of the last patient
Invasive disease-free survival (IDFS) - control cohort
大体时间:up to 96 months after inclusion of the last patient

Number of patients with breast tumor recurrence or death in the control cohort

up to 96 months after inclusion of the last patient
disease recurrence free survival (DRFS) - optimalisation cohort per-protocol population
大体时间:up to 96 months after inclusion of the last patient

time between inclusion and first distant recurrence or death from any cause in the per-protocol population of the optimisation cohort

up to 96 months after inclusion of the last patient
disease recurrence free survival (DRFS) - optimalisation cohort the intention-to-treat population
大体时间:up to 96 months after inclusion of the last patient

time between inclusion and first distant recurrence or death from any cause in the intention-to-treat population of the optimisation cohort population of the optimisation cohort

up to 96 months after inclusion of the last patient
disease recurrence free survival (DRFS) - control cohort
大体时间:up to 96 months after inclusion of the last patient

time between inclusion and first distant recurrence or death from any cause in the control cohort

up to 96 months after inclusion of the last patient
Recurrence-free survival (RFS) - optimalisation cohort per-protocol population
大体时间:up to 96 months after inclusion of the last patient

time between inclusion and invasive ipsilateral breast tumor recurrence, local-regional invasive recurrence, distant recurrence or death from any cause in the per-protocol population of the optimisation cohort;

up to 96 months after inclusion of the last patient
Recurrence-free survival (RFS) - optimalisation cohort the intention-to-treat population
大体时间:up to 96 months after inclusion of the last patient

time between inclusion and invasive ipsilateral breast tumor recurrence, local-regional invasive recurrence, distant recurrence or death from any cause in the the intention-to-treat population of the optimisation cohort;

up to 96 months after inclusion of the last patient
Recurrence-free survival (RFS) - control cohort
大体时间:up to 96 months after inclusion of the last patient

time between inclusion and invasive ipsilateral breast tumor recurrence, local-regional invasive recurrence, distant recurrence or death from any cause in the control cohort;

up to 96 months after inclusion of the last patient
Overal Survival (OS) - optimalisation cohort per-protocol population
大体时间:up to 96 months after inclusion of the last patient

time between inclusion and death from any cause in the per-protocol population of the optimisation cohort;

up to 96 months after inclusion of the last patient
Overal Survival (OS) - optimalisation cohort intention-to-treat population
大体时间:up to 96 months after inclusion of the last patient

time between inclusion and death from any cause in the the intention-to-treat population of the optimisation cohort;

up to 96 months after inclusion of the last patient
Overal Survival (OS) - control cohort
大体时间:up to 96 months after inclusion of the last patient

time between inclusion and death from any cause in the control cohort;

up to 96 months after inclusion of the last patient
Health related Quality of Life (HRQoL) - (European Organisation on Research and Treatment of Cancer) EORTC questionnaire QLQ-C30
大体时间:up to 2 years after inclusion

Difference in QoL assessed with the EORTC QLQ-C30 questionnaires between the optimisation and the control group. A higher score indicates a higher symptom burden.

up to 2 years after inclusion
Health related Quality of Life (HRQoL) - (European Organisation on Research and Treatment of Cancer) EORTC questionnaire QLQ-BR45
大体时间:up to 2 years after inclusion

Difference in QoL assessed with the EORTC QLQ-BR45 questionnaires between the optimisation and the control group. A higher score indicates a higher symptom burden.

up to 2 years after inclusion
Fear of recurrence
大体时间:up to 2 years after inclusion

Assessed with questionnaires to determine the difference in optimisation and control group

up to 2 years after inclusion
Worries about health
大体时间:up to 2 years after inclusion

Assessed with questionnaires to determine the difference in optimisation and control group. A higher score indicates a higher symptom burden.

up to 2 years after inclusion
Cost effectiveness measured by quality-adjusted-life years (QALYs)
大体时间:up to 2 years after inclusion

Measured per Quality-Adjusted Life Years (QALYs)

up to 2 years after inclusion
Cost effectiveness measured per incremental cost-effectiveness ratio (ICER)
大体时间:up to 2 years after inclusion

Measured per incremental cost-effectiveness ratio (ICER)

up to 2 years after inclusion

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Marleen Kok, MD、Antoni van Leeuwenhoek

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年4月15日

初级完成 (估计的)

2032年9月15日

研究完成 (估计的)

2034年9月15日

研究注册日期

首次提交

2024年6月7日

首先提交符合 QC 标准的

2024年6月20日

首次发布 (实际的)

2024年6月26日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

no IPD plan

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅